Clinical Trial Update: Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

View source ↗

Summary

A completed post-marketing surveillance trial evaluating the safety and efficacy of IBRANCE (palbociclib) in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IBRANCE (PALBOCICLIB)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasm | Status: COMPLETED